Pfizer and its partner, BioNTech, will request federal authorization to administer fourth doses of its COVID-19 vaccine to adults 65 and older.

The companies could jointly submit clinical data backing up the need for a second booster dose as soon as Tuesday, the Washington Post reported. The submission will include data collected in Israel, where government regulators have authorized another round of boosters in the senior population, which is at a higher risk of severe illness than younger people.